Breaking News Instant updates and real-time market news.

MKTX

MarketAxess

$332.76

-0.24 (-0.07%)

, LLL

L3 Technologies

$256.30

(0.00%)

17:28
06/24/19
06/24
17:28
06/24/19
17:28

S&P announces changes to S&P 400, 500, 600 indices

S&P Dow Jones Indices will make the following changes to the S&P 500, S&P MidCap 400 and S&P SmallCap 600: MarketAxess Holdings (MKTX) will replace L3 Technologies (LLL) in the S&P 500, Axon Enterprise (AAXN) will replace MarketAxess Holdings in the S&P MidCap 400, and Mesa Laboratories (MLAB) will replace Axon Enterprise in the S&P SmallCap 600 effective prior to the open of trading on Monday, July 1. Harris (HRS) is acquiring L3 Technologies in a deal expected to be completed on or about that date pending final approvals. USANA Health Sciences (USNA) will replace Fidelity Southern (LION) in the S&P SmallCap 600 effective prior to the open of trading on Monday, July 1. Ameris Bancorp (ABCB) is acquiring Fidelity Southern in a deal expected to be completed on or about that date pending final conditions. Xencor (XNCR) will replace HFF Inc. (HF) in the S&P SmallCap 600 effective prior to the open of trading on Tuesday, July 2. Jones Lang LaSalle (JLL) is acquiring HFF in a deal expected to be completed on or about that date pending final approvals.

MKTX

MarketAxess

$332.76

-0.24 (-0.07%)

LLL

L3 Technologies

$256.30

(0.00%)

AAXN

Axon

$73.22

-0.12 (-0.16%)

MLAB

Mesa Labs

$227.44

-3.4 (-1.47%)

HRS

Harris

$197.28

-0.07 (-0.04%)

USNA

Usana

$72.41

-0.58 (-0.79%)

LION

Fidelity Southern

$30.18

-0.06 (-0.20%)

ABCB

Ameris Bancorp

$37.76

(0.00%)

XNCR

Xencor

$33.86

-1.31 (-3.72%)

HF

HFF Inc.

$45.25

-0.29 (-0.64%)

JLL

Jones Lang LaSalle

$137.43

-2.075 (-1.49%)

  • 26

    Jun

  • 06

    Aug

  • 26

    Aug

MKTX MarketAxess
$332.76

-0.24 (-0.07%)

04/15/19
RSBL
04/15/19
INITIATION
Target $255
RSBL
Neutral
MarketAxess initiated with a Neutral at Rosenblatt
Rosenblatt analyst Kenneth Hill initiated MarketAxess with a Neutral rating and $255 price target.
06/12/19
BUCK
06/12/19
DOWNGRADE
Target $245
BUCK
Underperform
Enthusiasm around MarketAxess outlook 'excessive,' says Buckingham
Buckingham analyst Hugh Miller downgraded MarketAxess to Underperform from Neutral, saying that while he views the company as "well managed" and thinks it is best positioned to benefit from the electronification of the corporate bond markets, he feels investor enthusiasm regarding its growth outlook has become "excessive." Miller, who maintains a $245 price target, contends that management can successfully execute on the market share front and even a reversion of industry volume growth to longer-term historical averages could weigh on the stock.
01/10/19
BUCK
01/10/19
INITIATION
Target $222
BUCK
Neutral
MarketAxess initiated with a Neutral at Buckingham
Buckingham analyst Hugh Miller started MarketAxess with a Neutral rating and $222 price target, stating that though he views it as having a premiere franchise he thinks investors will need to see signs of an inflection in market share gains and/or upside to its EPS growth outlook before the stock appreciates further given it currently trades at a premium to its five year historical average.
06/12/19
BUCK
06/12/19
DOWNGRADE
BUCK
Underperform
MarketAxess downgraded to Underperform from Neutral at Buckingham
Buckingham analyst Hugh Miller downgraded MarketAxess to Underperform from Neutral citing valuation concerns.
LLL L3 Technologies
$256.30

(0.00%)

05/08/19
ARGS
05/08/19
NO CHANGE
Target $200
ARGS
Buy
Harris price target raised to $200 from $170 at Argus
Argus analyst John Eade raised his price target on Harris (HRS) to $200 and kept his Buy rating, saying the stock looks "favorably valued" at current levels. The analyst is positive on the company's business trends and the benefits of its planned L3 Technologies (LLL) acquisition while also pointing to the management's recent 20% dividend increase as a sign of confidence in its outlook.
05/02/19
RHCO
05/02/19
NO CHANGE
Target $265
RHCO
Buy
L3 Technologies price target raised to $265 from $228 at SunTrust
SunTrust analyst Michael Ciarmoli raised his price target on L3 Technologies (LLL) to $265 and kept his Buy rating after its Q1 beat on revenue and earnings driven by "strong" organic growth. The analyst also cites the company's "robust order flow" and expects the "powerful combination" with Harris (HRS) to benefit from the current defense spending trends of upgraded "comms, radars, and ISR capabilities."
05/02/19
FBCO
05/02/19
NO CHANGE
Target $258
FBCO
Outperform
L3 Technologies price target raised to $258 from $232 at Credit Suisse
Credit Suisse analyst Robert Spingarn raised his price target for L3 Technologies to $258 from $232, saying that the company "came out swinging" in what will likely prove to be its last quarter as a standalone public company, with a strong showing across all key financial metrics. The analyst reiterates an Outperform rating on the shares.
05/29/19
LEHM
05/29/19
NO CHANGE
Target $245
LEHM
Overweight
Harris price target raised to $245 from $205 at Barclays
Barclays analyst David Strauss raised his price target for Harris (HRS) to $245 from $205 saying his updated merger model indicates additional upside compared to his prior forecast, with "well above peer group" growth in 2020-2021 on both an adjusted earnings and free cash flow basis. Even with the stock's recent outperformance, he estimates the combined Harris, L3 Technologies (LLL) still trades at a ~10% discount to defense peers. Strauss keeps an Overweight rating on Harris shares.
AAXN Axon
$73.22

-0.12 (-0.16%)

05/24/19
IMPC
05/24/19
DOWNGRADE
Target $68
IMPC
In-Line
Axon downgraded to In-Line from Outperform at Imperial Capital
Imperial Capital analyst Jeff Kessler downgraded Axon Enterprise to In-Line from Outperform while raising his price target for the shares to $68 from $62. The analyst cites valuation for the downgrade following the company's Q1 results. He believes, however, that Axon's efforts to create an end-to-end public safety platform, from weapons to data and records management, is likely to result in continued growth for the next several years.
05/08/19
MSCO
05/08/19
NO CHANGE
Target $71
MSCO
Overweight
Axon price target raised to $71 ahead of earnings at Morgan Stanley
Morgan Stanley analyst James Faucette raised his price target on Axon shares to $71 from $65 ahead of the company's earnings report on May 9, stating that he came away from last week's Accelerate User Conference more convinced that the company appears poised to benefit from 5G and that Axon can profitably improve emergency services. Faucette, who said he thinks Axon's "market leading" Evidence.com software offering remains underappreciated, keeps an Overweight rating on the shares.
04/08/19
04/08/19
UPGRADE
Target $79

Strong Buy
Axon upgraded to Strong Buy at Raymond James
As previously reported, Raymond James analyst Brian Gesuale upgraded Axon to Strong Buy from Outperform, with a $79 price target, while laying out the case for a $100 share price exiting 2021. The analyst believes investors are underestimating the compounding power of a growing subscriber base, rising ARPUs, and the ongoing transformation of the business towards cloud-based revenue. Despite the clear mix shift to higher-multiple cloud revenue, shares remain in a similar multiple channel to when the company was a standalone hardware business, he adds.
06/20/19
JPMS
06/20/19
NO CHANGE
Target $81
JPMS
Overweight
Axon Enterprise price target raised to $81 from $73 at JPMorgan
JPMorgan analyst Mark Strouse raised his price target for Axon Enterprise to $81 from $73 after introducing his estimates for fiscal 2021. The analyst expects the company's revenue growth to remain "elevated" through fiscal 2021 and for margins to continue to expand, consistent with management's long-term targets. Even with the shares up 60% year-to-date, Strouse recommends investors add to positions ahead of near-term catalysts and an expected acceleration in revenue and earnings growth during the second half of 2019. He expects Axon's AB3 cameras to be commercially available by early Q3, "likely resulting in strong contract announcement activity." The analyst also believes AB3's live-streaming LTE capability could allow Axon to penetrate adjacent markets such as EMS and fire departments. Strouse maintains an Overweight rating on the shares, which closed yesterday up $3.86 to $69.90 despite a short research report issued by Spruce Point.
MLAB Mesa Labs
$227.44

-3.4 (-1.47%)

03/13/19
SIDC
03/13/19
INITIATION
SIDC
Neutral
Mesa Labs re-initiated with a Neutral at Sidoti
HRS Harris
$197.28

-0.07 (-0.04%)

01/30/19
ARGS
01/30/19
NO CHANGE
Target $170
ARGS
Buy
Harris price target raised to $170 from $160 at Argus
Argus analyst John Eade raised his price target on Harris to $170 and kept his Buy rating after its Q2 earnings beat. The analyst says the company's business trends are positive, and its recent 20% dividend increase signals the management's confidence in its outlook. Despite the 9% post-earnings jump, Eade says Harris shares are "favorably valued" at current levels.
USNA Usana
$72.41

-0.58 (-0.79%)

10/24/18
PIVT
10/24/18
UPGRADE
Target $135
PIVT
Buy
Pivotal upgrades Usana to Buy on 'impressive' sales momentum
Pivotal Research analyst Timothy Ramey upgraded Usana to Buy from Hold with an unchanged price target of $135. The company is seeing "impressive" sales momentum following the "blow-out" Q3 results, Ramey tells investors in a research note. The analyst won't be surprised if Usana "gains momentum as it rolls into 2019" and he points out the stock is down about 30% from summer highs.
04/16/19
TIGR
04/16/19
INITIATION
TIGR
Buy
Usana initiated with a Buy at Tigress Financial
Tigress Financial analyst Ivan Feinseth initiated Usana with a Buy rating, citing his view of its strong sales growth trends and strong innovation pipeline. He believes the inherent operating leverage in its direct selling model will continue to drive increased return on capital and profits and views the recent pullback in the stock as a buying opportunity.
04/03/19
STFL
04/03/19
NO CHANGE
Target $43
STFL
Sell
Stifel reiterates Sell rating on Nu Skin after Usana profit warning
After Usana (USNA) announced softer than expected preliminary Q1 results, which it attributed to sales in China and unfavorable media coverage on the direct selling industry there, Stifel analyst Mark Astrachan reiterated his Sell rating and $43 price target on shares of competitor Nu Skin (NUS). Despite Nu Skin having less exposure to nutrition than Usana, Astrachan continues to worry about increasing scrutiny on Nu Skin and thinks the potential for a more thorough investigation by the Chinese government remains a risk.
10/25/18
SIDC
10/25/18
UPGRADE
SIDC
Buy
Usana upgraded to Buy from Neutral at Sidoti
LION Fidelity Southern
$30.18

-0.06 (-0.20%)

12/19/18
SDLR
12/19/18
UPGRADE
Target $41
SDLR
Buy
Ameris Bancorp upgraded to Buy from Hold at Sandler O'Neill
Sandler O'Neill analyst Casey Whitman upgraded Ameris Bancorp (ABCB) to Buy from Hold stating that the pullback has been severe enough that he believes that it is time to buy with the stock now down 43% over the last six months. Even based on estimates that are more conservative than the Street, Whitman sees the company generating EPS growth of 24% in 2019, he noted. Remarking on the company's agreement to acquire Fidelity Southern (LION), Whitman said the deal was a surprise but he thinks it makes sense to combine these two banks given Fidelity's valuable lower-costing core deposit base centered in Atlanta. The analyst, who also sees an opportunity for scale and efficiency in the mortgage segment, has a $41 price target on Ameris shares.
05/15/19
SPHN
05/15/19
NO CHANGE
SPHN
Stephens replaces CenterState with Ameris as 2019 Best Idea
Stephens analyst Tyler Stafford made Ameris Bancorp (ABCB) his new 2019 Best Idea, replacing CenterState Bank (CSFL). Ameris' current valuation is "entirely too cheap" considering its "meaningful tailwinds and favorable outlook" for the remainder of 2019, Stafford tells investors in a research note. The analyst sees the company's "already impressive" profitability profile accelerating even further with the Fidelity Southern (LION) deal. He has an Overweight rating on Ameris with a $52 price target.
12/19/18
SDLR
12/19/18
UPGRADE
Target $33
SDLR
Buy
Fidelity Southern upgraded to Buy from Hold at Sandler O'Neill
Sandler O'Neill analyst Casey Whitman upgraded Fidelity Southern (LION) to Buy from Hold, stating that he thinks the rationale to combine with Ameris Bancorp (ABCB) "makes a lot of sense" given Fidelity's solid deposit base and scarcity value in Altanta. Whitman thinks Ameris is paying a reasonable price and Fidelity shareholders are receiving valuable consideration, making the deal "a win for both sides." Given the all-stock deal, he raised his price target on Fidelity Southern to $33 from $25 to reflect the conversion rate and his $41 price target for Ameris shares.
01/29/19
RHCO
01/29/19
UPGRADE
Target $48
RHCO
Buy
Ameris Bancorp upgraded to Buy from Hold at SunTrust
SunTrust analyst Jennifer Demba upgraded Ameris Bancorp (ABCB) to Buy and raises her price target to $48 from $36. The analyst notes that the acquisition of Fidelity Southern (LION) announced last month will give it a "significant deposit platform in economically vibrant Atlanta, reduce its cost of funds and further improve efficiency." Demba adds that she is less concerned with the latter's rate of loan growth, noting that although the management targets an expansion of over 10%, it has also promised to maintain the bank's underwriting standards.
ABCB Ameris Bancorp
$37.76

(0.00%)

01/29/19
RHCO
01/29/19
UPGRADE
RHCO
Buy
Ameris Bancorp upgraded to Buy from Hold at SunTrust
XNCR Xencor
$33.86

-1.31 (-3.72%)

06/12/19
MZHO
06/12/19
INITIATION
Target $52
MZHO
Buy
Xencor initiated with a Buy at Mizuho
Mizuho analyst Mara Goldstein initiated Xencor with a Buy rating and $52 price target, stating that the company has a validated platform and a proprietary pipeline. She thinks that general concern around bispecifics and pipeline-specific worries are not "insurmountable," Goldstein added.
04/12/19
GUGG
04/12/19
INITIATION
Target $42
GUGG
Buy
Xencor initiated with a Buy at Guggenheim
Guggenheim analyst Michael Schmidt started Xencor with a Buy rating and $42 price target. The company has a "deep" clinical pipeline of bispecific T-cell engagers and dual checkpoint / co-stimulatory antibodies with early clinical data readouts through the second half of 2019 that represent potential upside, Schmidt tells investors in a research note.
03/27/19
BREN
03/27/19
INITIATION
Target $45
BREN
Buy
Xencor initiated with a Buy at Berenberg
Berenberg analyst Shanshan Xu initiated Xencor with a Buy and $45 price target saying he sees a turning point ahead following a setback earlier this year due to the partial clinical hold on onf of its CD3 T-cell bispecific antibodies. Xu believes the ramp of Ultomiris royalties and the potential positive data and regulatory approval of MOR-208 will validate Xencor's platform and increase confidence in its broader pipeline, providing a door for further partnerships.
03/14/19
RAJA
03/14/19
INITIATION
Target $40
RAJA
Outperform
Xencor initiated with an Outperform at Raymond James
Raymond James analyst Dane Leone initiated Xencor with an Outperform rating and a price target of $40, citing the company's "multiple programs and development partnerships across a range of therapeutic indications." The analyst contends that the next 12 months will be a "clinical inflection point for the wholly owned bi-specific antibody programs targeting oncology", adding that he is "optimistic that the current partial hold on the Xmab14045 program could be lifted near-term". Leone further notes that his sales model does not account for obexelimab until a partnership has been established, but he is "optimistic for a partnership to occur within the next 12 months".
HF HFF Inc.
$45.25

-0.29 (-0.64%)

JLL Jones Lang LaSalle
$137.43

-2.075 (-1.49%)

05/10/19
05/10/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. 3D Systems (DDD) upgraded to Neutral from Underweight at JPMorgan with analyst Paul Coster noting the stock is down 25% this week after posting "lackluster" Q1 results. 2. Jones Lang LaSalle (JLL) upgraded to Buy from Neutral at Goldman Sachs with analyst Andrew Rosivach saying the company's earnings declined in Q1 due to tough comps, but this should reverse quickly. 3. Ford (F) upgraded to Buy from Neutral at BofA/Merrill with analyst John Murphy stating the company's earnings are starting to hit a "sustainable inflection" due to favorable product cadence in the North America market and its restructuring efforts. 4. Whirlpool (WHR) upgraded to Buy from Neutral at Longbow with analyst David MacGregor seeing earnings upside from better than expected North American margin performance, a "gradually improving" environment in the EMEA and a favorable cyclical turn in Latin America. 5. Anthem (ANTM), Centene (CNC), and UnitedHealth (UNH) upgraded to Buy from Neutral at Citi with analyst Ralph Giacobbe the magnitude of the selloff in managed care stocks on fears of Medicare for All has been "extreme and overdone". This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
05/10/19
GSCO
05/10/19
UPGRADE
Target $206
GSCO
Buy
Jones Lang LaSalle upgraded to Buy from Neutral at Goldman Sachs
Goldman Sachs analyst Andrew Rosivach upgraded Jones Lang LaSalle to Buy from Neutral and raised his price target for the shares to $206 from $183. The company's earnings declined in Q1 due to tough comps, but this should reverse quickly, Rosivach tells investors in a research note. He expects Q2 to present easier comps and believes the macro backdrop is strong for capital markets and leasing. The analyst recommends using the pullback in Jones Lang LaSalle shares as a buying opportunity. Rosivach sees 12 month return potential of 47%, including dividends.
05/31/19
05/31/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Mallinckrodt (MNK) downgraded to Neutral from Overweight at Piper Jaffray with analyst David Amsellem stating last week's developments regarding Acthar in the Medicaid setting, along with as much as a $600M Centers for Medicare & Medicaid Services-related liability, "essentially blew" his prior investment thesis to "smithereens." 2. Nucor (NUE) downgraded to Underperform from Buy at BofA/Merrill with analyst Timna Tanners incorporating a lower near-term forecast for prices, especially for sheet and rebar, and a lower 2021-2022 forecast given expectations for a looming glut in steel. 3. J.Jill (JILL) downgraded to Hold from Buy at Deutsche Bank with analyst Lorraine Hutchinson stating that she expects the stock's multiple to contract due to the company's slower growth. 4. Nutanix (NTNX) downgraded to Neutral from Overweight at Piper Jaffray with analyst Andrew Nowinski citing the company's "continued execution issues," which he attributes partially to increasing competition. 5. Zuora (ZUO) downgraded to Buy from Strong Buy at Needham with analyst Scott Berg saying that the stock could be "dead money" for the next 1-2 quarters, noting that the sales issues are more concerning than the product issues and may require a change in sales leadership. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
04/17/19
04/17/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Qualcomm (QCOM) upgraded to Overweight from Neutral at JPMorgan and to Outperform from In Line at Evercore ISI. 2. Domino's Pizza (DPZ) upgraded to Overweight from Equal Weight at Morgan Stanley with analyst John Glass saying he thinks the stock's current price reflects 2-3% blended global same store sales growth over the next two years, which he views as too bearish based on its track record as a "best in class operator." 3. TSYS (TSS) upgraded to Buy from Neutral at Goldman Sachs with analyst James Schneider saying the company's new portfolios are driving revenue growth while improving margin expansion is driving earnings acceleration. 4. Omnicom (OMC) upgraded to Equal Weight from Underweight at Barclays. 5. Jones Lang LaSalle (JLL) upgraded to Outperform from Market Perform at Keefe Bruyette with analyst Jade Rahmani saying she sees an attractive entry point following the recent underperformance of the shares. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

TODAY'S FREE FLY STORIES

PYPL

PayPal

$118.65

-1.22 (-1.02%)

, V

Visa

$179.18

-1.34 (-0.74%)

08:31
07/20/19
07/20
08:31
07/20/19
08:31
Periodicals
MasterCard, Visa among best stocks to play fintech boom, Barron's says »

The fintech units within…

PYPL

PayPal

$118.65

-1.22 (-1.02%)

V

Visa

$179.18

-1.34 (-0.74%)

MA

MasterCard

$275.51

-1.11 (-0.40%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

  • 24

    Jul

  • 30

    Jul

USB

U.S. Bancorp

$54.98

-0.2 (-0.36%)

, SBNY

Signature Bank

$123.87

1.07 (0.87%)

08:28
07/20/19
07/20
08:28
07/20/19
08:28
Periodicals
KeyCorp, U.S. Bancorp better positioned for Fed rate cut, Barron's says »

KeyCorp (KEY), Signature…

USB

U.S. Bancorp

$54.98

-0.2 (-0.36%)

SBNY

Signature Bank

$123.87

1.07 (0.87%)

KEY

KeyCorp

$17.45

0.15 (0.87%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

  • 29

    Aug

  • 16

    Oct

CMG

Chipotle

$746.80

-17.43 (-2.28%)

08:24
07/20/19
07/20
08:24
07/20/19
08:24
Periodicals
Chipotle stock made 'stunning' comeback, Barron's says »

Chipotle's stock is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

  • 25

    Sep

BYND

Beyond Meat

$176.65

6.28 (3.69%)

07:40
07/20/19
07/20
07:40
07/20/19
07:40
Periodicals
Beyond Meat could spike after earnings, Barron's says »

After rising so…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Jul

NFLX

Netflix

$315.10

-10.04 (-3.09%)

07:37
07/20/19
07/20
07:37
07/20/19
07:37
Periodicals
Netflix's problems have only just begun, Barron's says »

Netflix has a problem and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Aug

AMZN

Amazon.com

$1,964.78

-13.57 (-0.69%)

, TGT

Target

$88.02

-0.48 (-0.54%)

07:34
07/20/19
07/20
07:34
07/20/19
07:34
Periodicals
Time to aim higher on Target's stock, Barron's says »

As retailers have…

AMZN

Amazon.com

$1,964.78

-13.57 (-0.69%)

TGT

Target

$88.02

-0.48 (-0.54%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

  • 21

    Aug

  • 19

    Sep

  • 25

    Sep

AMZN

Amazon.com

$1,964.78

-13.57 (-0.69%)

, FDX

FedEx

$167.08

1.69 (1.02%)

07:31
07/20/19
07/20
07:31
07/20/19
07:31
Periodicals
FedEx ups game amid e-commerce growth, Barron's says »

It is time to embrace…

AMZN

Amazon.com

$1,964.78

-13.57 (-0.69%)

FDX

FedEx

$167.08

1.69 (1.02%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

  • 30

    Jul

  • 31

    Jul

  • 17

    Sep

  • 13

    Nov

AMZN

Amazon.com

$1,964.78

-13.57 (-0.69%)

, MSFT

Microsoft

$136.62

0.33 (0.24%)

07:27
07/20/19
07/20
07:27
07/20/19
07:27
On The Fly
Week in review: How Trump's policies moved stocks »

Catch up on the top…

AMZN

Amazon.com

$1,964.78

-13.57 (-0.69%)

MSFT

Microsoft

$136.62

0.33 (0.24%)

ORCL

Oracle

$57.55

-0.58 (-1.00%)

AZN

AstraZeneca

$40.11

-0.61 (-1.50%)

BMY

Bristol-Myers

$43.32

-0.72 (-1.63%)

LLY

Eli Lilly

$106.75

-1.57 (-1.45%)

GSK

GlaxoSmithKline

$40.97

-0.44 (-1.06%)

JNJ

Johnson & Johnson

$130.41

-1.62 (-1.23%)

MRK

Merck

$81.39

-1.28 (-1.55%)

NVS

Novartis

$93.58

-0.715 (-0.76%)

PFE

Pfizer

$42.78

-0.28 (-0.65%)

RHHBY

Roche

$0.00

(0.00%)

SNY

Sanofi

$41.94

-0.01 (-0.02%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jul

  • 23

    Jul

  • 23

    Jul

  • 23

    Jul

  • 23

    Jul

  • 24

    Jul

  • 25

    Jul

  • 25

    Jul

  • 25

    Jul

  • 29

    Jul

  • 30

    Jul

  • 30

    Jul

  • 30

    Jul

  • 03

    Aug

  • 06

    Aug

  • 06

    Aug

  • 08

    Aug

  • 18

    Aug

  • 19

    Aug

  • 26

    Aug

  • 27

    Aug

  • 28

    Aug

  • 02

    Sep

  • 09

    Sep

  • 16

    Sep

  • 16

    Sep

  • 20

    Sep

  • 23

    Sep

  • 25

    Sep

  • 02

    Oct

  • 15

    Oct

  • 04

    Nov

BHVN

Biohaven Pharmaceutical

$44.16

-0.61 (-1.36%)

18:12
07/19/19
07/19
18:12
07/19/19
18:12
Hot Stocks
Biohaven receives CRL from FDA for application seeking NURTEC approval »

Biohaven Pharmaceutical…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Sep

CE

Celanese

$107.01

0.9 (0.85%)

18:01
07/19/19
07/19
18:01
07/19/19
18:01
Hot Stocks
Celanese announces acetyl intermediates price increases »

Celanese Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

F

Ford

$10.20

-0.06 (-0.58%)

17:48
07/19/19
07/19
17:48
07/19/19
17:48
Periodicals
Ford plans to lay off 185 employees at Ontario plant, Reuters reports »

A union local said that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jul

  • 23

    Oct

RTN

Raytheon

$178.55

2.45 (1.39%)

17:48
07/19/19
07/19
17:48
07/19/19
17:48
Hot Stocks
Raytheon awarded $191.01M Air Force contract modification »

Raytheon has been awarded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

UTX

United Technologies

$132.37

1.08 (0.82%)

17:44
07/19/19
07/19
17:44
07/19/19
17:44
Hot Stocks
United Technologies awarded $253.71M Air Force contract »

United Technologies has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

LMT

Lockheed Martin

$356.90

0.675 (0.19%)

17:40
07/19/19
07/19
17:40
07/19/19
17:40
Hot Stocks
Lockheed Martin awarded $1.47B Missile Defense Agency contract modification »

Lockheed Martin has been…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

ARES

Ares Management

$28.13

-0.305 (-1.07%)

17:33
07/19/19
07/19
17:33
07/19/19
17:33
Syndicate
Breaking Syndicate news story on Ares Management »

Ares Management files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Jul

  • 06

    Aug

HAFC

Hanmi Financial

$21.68

-0.105 (-0.48%)

17:33
07/19/19
07/19
17:33
07/19/19
17:33
Hot Stocks
Hanmi Financial to delay release of Q2 results »

Hanmi Financial announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

PAYS

Paysign

$17.49

-0.48 (-2.67%)

17:32
07/19/19
07/19
17:32
07/19/19
17:32
Syndicate
Breaking Syndicate news story on Paysign »

Paysign files $150M mixed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MEOH

Methanex

$43.19

0.83 (1.96%)

17:28
07/19/19
07/19
17:28
07/19/19
17:28
Hot Stocks
Methanex reaches final investment decision on methanol plant in Geismar, LA »

Methanex Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Aug

17:17
07/19/19
07/19
17:17
07/19/19
17:17
Conference/Events
Credit Suisse biotech analysts to hold an analyst/industry conference call »

Biotech Analysts provide…

17:14
07/19/19
07/19
17:14
07/19/19
17:14
Conference/Events
UBS retail/hardlines analyst to hold an analyst/industry conference call »

Retail/Hardlines Analyst…

SHIP

Seanergy Marine

$0.64

-0.0425 (-6.25%)

17:05
07/19/19
07/19
17:05
07/19/19
17:05
Hot Stocks
Seanergy Maritime receives noncompliance notice from Nasdaq »

Seanergy Maritime…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SONM

Sonim

$13.42

0.24 (1.82%)

16:41
07/19/19
07/19
16:41
07/19/19
16:41
Conference/Events
Sonim management to meet with Oppenheimer »

Meetings to be held on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jul

  • 25

    Jul

  • 26

    Jul

  • 12

    Sep

KINS

Kingstone Companies

$8.81

0.09 (1.03%)

16:30
07/19/19
07/19
16:30
07/19/19
16:30
Hot Stocks
Kingstone names Barry Goldstein CEO »

Kingstone Companies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Aug

  • 09

    Aug

16:30
07/19/19
07/19
16:30
07/19/19
16:30
Options
Preliminary option volume of 22.6M today »

Preliminary option volume…

BA

Boeing

$377.34

16.17 (4.48%)

, MSFT

Microsoft

$136.62

0.33 (0.24%)

16:24
07/19/19
07/19
16:24
07/19/19
16:24
On The Fly
Fly Intel: Wall Street's top stories for Friday »

Stocks were tentatively…

BA

Boeing

$377.34

16.17 (4.48%)

MSFT

Microsoft

$136.62

0.33 (0.24%)

AMZN

Amazon.com

$1,964.78

-13.57 (-0.69%)

AAPL

Apple

$202.62

-3.02 (-1.47%)

WMT

Walmart

$113.91

-0.77 (-0.67%)

DIS

Disney

$139.86

-1.76 (-1.24%)

GCI

Gannett

$9.43

1.53 (19.37%)

CRWD

Crowdstrike

$83.50

10.75 (14.78%)

SKX

Skechers

$39.00

4.25 (12.23%)

PACB

Pacific Biosciences

$5.34

-0.53 (-9.03%)

ILMN

Illumina

$293.10

-5.44 (-1.82%)

CHWY

Chewy

$30.70

-2.09 (-6.37%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jul

  • 25

    Jul

  • 29

    Jul

  • 30

    Jul

  • 03

    Aug

  • 06

    Aug

  • 06

    Aug

  • 08

    Aug

  • 15

    Aug

  • 03

    Sep

  • 25

    Sep

  • 13

    Nov

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.